William Blair Has Bearish Forecast for CRL FY2025 Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Equities researchers at William Blair lowered their FY2025 earnings per share (EPS) estimates for shares of Charles River Laboratories International in a research note issued on Thursday, November 6th. William Blair analyst M. Smock now anticipates that the medical research company will post earnings per share of $10.22 for the year, down from their previous forecast of $10.29. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share. William Blair also issued estimates for Charles River Laboratories International’s Q4 2025 earnings at $2.32 EPS, Q1 2026 earnings at $2.67 EPS, Q3 2026 earnings at $2.67 EPS, Q4 2026 earnings at $2.51 EPS and FY2026 earnings at $10.61 EPS.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, November 5th. The medical research company reported $2.43 earnings per share for the quarter, topping analysts’ consensus estimates of $2.32 by $0.11. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $990.43 million. During the same quarter in the prior year, the company posted $2.59 earnings per share. Charles River Laboratories International’s quarterly revenue was down .5% on a year-over-year basis.

CRL has been the subject of several other research reports. Baird R W upgraded shares of Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 6th. JPMorgan Chase & Co. lifted their price target on shares of Charles River Laboratories International from $160.00 to $165.00 and gave the company a “neutral” rating in a research report on Thursday, November 6th. Weiss Ratings reissued a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, October 8th. TD Cowen dropped their price objective on Charles River Laboratories International from $205.00 to $197.00 and set a “buy” rating for the company in a research note on Monday. Finally, Jefferies Financial Group raised Charles River Laboratories International from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $142.00 to $195.00 in a report on Tuesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $188.29.

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $173.62 on Monday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.10 and a current ratio of 1.36. Charles River Laboratories International has a one year low of $91.86 and a one year high of $221.60. The firm has a market capitalization of $8.54 billion, a P/E ratio of -130.54, a PEG ratio of 4.83 and a beta of 1.53. The company’s fifty day moving average is $168.36 and its two-hundred day moving average is $156.46.

Insider Activity

In related news, EVP Joseph W. Laplume sold 800 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $157.60, for a total value of $126,080.00. Following the sale, the executive vice president owned 24,116 shares of the company’s stock, valued at approximately $3,800,681.60. This represents a 3.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Charles River Laboratories International

Institutional investors have recently made changes to their positions in the stock. Cambridge Investment Research Advisors Inc. boosted its stake in shares of Charles River Laboratories International by 6.8% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 1,926 shares of the medical research company’s stock valued at $290,000 after acquiring an additional 123 shares during the last quarter. Teacher Retirement System of Texas purchased a new position in Charles River Laboratories International in the 1st quarter valued at about $1,231,000. Concurrent Investment Advisors LLC acquired a new stake in shares of Charles River Laboratories International during the 1st quarter worth about $213,000. New York State Common Retirement Fund grew its holdings in shares of Charles River Laboratories International by 16.7% during the first quarter. New York State Common Retirement Fund now owns 131,820 shares of the medical research company’s stock worth $19,842,000 after buying an additional 18,894 shares in the last quarter. Finally, Signaturefd LLC raised its position in shares of Charles River Laboratories International by 26.8% in the first quarter. Signaturefd LLC now owns 1,300 shares of the medical research company’s stock valued at $196,000 after buying an additional 275 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).